Reaching Others University at Buffalo - The State University of New York
Skip to Content
Richard                        Bankert

Richard B. Bankert VMD, PhD

Department of Microbiology and Immunology

Professor of Microbiology

 
top-left cornertop-right corner
Professional Summary:

I have over 25 years of experience with the design, development and use of immunodeficient mouse human tumor xenograft models to study the interaction of inflammatory leukocytes and fibroblasts with tumor cells in human lung and ovarian tumor microenvironments. My co-investigators and I have established that tumor-associated T cells are hypo-responsive to activation via the T cell receptor (TCR). We determined that the failure of these cells to respond to activation signals is due to the disruption of the TCR signaling cascade that occurs at or just proximal to the activation of PLC-γ. We have found that an identical TCR signaling arrest occurs in human T cells present within chronic inflammatory tissues. Using human tumor xenograft models my students and postdoctoral fellows established that a local and sustained release of IL-12 into the tumor microenvironment activates the quiescent tumor associated T cells to produce and secrete IFN-γ that mobilizes an immune mediated eradication of the tumor. Based upon these preclinical studies we have begun a Phase I clinical trial to test the safety and feasibility of delivering low and sustained doses of recombinant human IL-12 directly into patients’ tumors. Most recently we have determined that lipids present within human ovarian tumor ascites fluids mediate a reversible arrest in the TCR signaling pathway of ovarian tumor-associated T cells. A major focus of my laboratory is to structurally identify the immunoinhibitory factors present within the tumor ascites fluids, determine the mechanism by which they arrest the TCR signaling, and using a novel humanized mouse model to preclinically test whether the TCR signaling arrest can be reversed in tumor-associated T cells or prevented from occurring in T cells upon entry into the tumor microenvironment by eliminating or blocking the lipid mediated disruption of the TCR signaling cascade.

Education and Training:
  • PhD, Immunology, University of Pennsylvania (1973)
  • VMD, Vet. Medicine, University of Pennsylvania (1968)
  • BA, Chem. & Biol., Gettysburg College (1962)
Employment:
  • Professor, State University of New York at Buffalo (2001-present)
  • Professor, Immunology, Roswell Park Div. of the State University of New York at Buffalo (1991-present)
  • Associate Chief Cancer Research Scientist VI, Roswell Park Cancer Institute (1982–1996)
  • Associate Professor, Immunology, Roswell Park Div of State University of New York at Buffalo (1988–1991)
  • Cancer Research Scientist V, Molecular Immunology, Roswell Park Cancer Institute (1978–1983)
  • Cancer Research Scientist IV, Molecular Immunology, Roswell Park Cancer Institute (1977–1978)
  • Cancer Research Scientist III, Molecular Immunology, Roswell Park Cancer Institute (1976–1977)
  • Cancer Research Scientist II, Molecular Immunology, Roswell Park Cancer Institute (1973–1976)
  • Postdoctoral Research Fellow in Immunology, Dept. Pathobiology, University of Pennsylvania (1970–1973)
  • Postdoctoral Research Fellow, University of Pennsylvania, School of Veterinary Medicine (1968–1970)
Awards and Honors:
  • Chancellor's Award for Excellence (2013)

Grants and Sponsored Research:
  • December 2007–November 2018
    Re-activating memory T cells in the microenvironment of human tumors
    NCI
    Role: Principal Investigator
    $217,764
  • July 2011–January 2015
    Development and pharmacology of novel lipidic rAHF
    NHLBI
    Role: Co-Investigator
  • July 2004–January 2015
    CD4+ memory T-cells in human tumor microenvironment
    NCI
    Role: Principal Investigator
    $198,947
  • July 2005–June 2006
    Product Development Fund
    University at Buffalo
    Role: Co-Investigator
    $33,000
  • January 2001–January 2006
    VHIg Peptide Vaccine Strategies for B-Cell Lymphomas
    NIH
    Role: Principal Investigator
    $150,000
  • January 2000–January 2004
    VHIg Peptide Vaccines for Human B-Cell Malignancies
    NIH
    Role: Principal Investigator
    $224,784
  • January 2000–December 2002
    A Tumor VH Peptide Vaccine for Patients with Non-Hodgkins Lymphoma
    NIH
    Role: Co-Investigator
    $100,000
  • January 1997–December 2002
    Immunity and Immunotherapy of Human Cancer in SCID Mice
    NIH
    Role: Principal Investigator
    $95,750
  • January 1991–December 2002
    Factors Affecting Human Lung Tumor Growth in SCID Mice
    NIH
    Role: Principal Investigator
    $194,866
  • January 2000–January 2002
    Bioadhesive Microspheres for Colon Cancer Therapy
    NIH
    Role: Co-Principal Investigator
    $194,000
  • January 1998–December 2001
    Immunology/CTLA4
    Pfizer, Inc.
    Role: Principal Investigator
    $64,000
See All (11 Total) >
Patents:
  • method of preparation of liposomes Composition and method of preparation of liposomal microparticulate IL-12 for immunotherapy (2010)
  • Preparation of Liposomes Compositions and methods of preparation of liposomal microparticulate IL-12. (2006)
  • Immunoassays and fractionation Microflotation devices used for immunoassays and cell/molecular fractionation (1991)
  • Cells and their use Coated Cells and Their Use (1985)

Journal Articles:
  • Simpson-Abelson MR, Loyall JL, Lehman HK, Barnas JL, Minderman H, O‘Loughlin KL, Wallace PK, George TC, Peng P, Kelleher RJ, Odunsi K, Bankert RB. Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells. Cancer Immun. 2013; 13.
  • Gaitonde P, Ramakrishnan R, Chin J, Kelleher RJ, Bankert RB, Balu-Iyer SV. Exposure to factor VIII protein in the presence of phosphatidylserine induces hypo-responsiveness toward factor VIII challenge in hemophilia A mice. J Biol Chem. 2013; 288(24).
  • Lehman HK, Simpson-Abelson MR, Conway TF, Jr, Kelleher RJ, Bernstein JM, Bankert RB. Memory T cells in the chronic inflammatory microenvironment of nasal polyposis are hyporesponsive to signaling through the T cell receptor. J Assoc Res Otolaryngol. 2012; 13(3).
  • Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci. 2012; 101(6).
  • Bernstein JM, Lehman HK, Lis M, Sands A, Wilding GE, Shultz L, Bankert RB, Bobek LA. Humanized mouse model used to monitor MUC gene expression in nasal polyps and to preclinically evaluate the efficacy of montelukast in reducing mucus production. Ann Otol Rhinol Laryngol. 2012; 121(5).
  • Bernstein JM, Brooks SP, Lehman HK, Pope L, Sands A, Shultz LD, Bankert RB. Human nasal polyp microenvironments maintained in a viable and functional state as xenografts in NOD-scid IL2rgamma(null) mice. Ann Otol Rhinol Laryngol. 2009; 118(12).
  • Simpson-Abelson MR, Purohit VS, Pang WM, Iyer V, Odunsi K, Demmy TL, Yokota SJ, Loyall JL, Kelleher RJ, Balu-Iyer S, Bankert RB. IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. Clin Immunol. 2009; 132(1).
  • Simpson-Abelson MR, Sonnenberg GF, Takita H, Yokota SJ, Conway TF, Kelleher RJ, Shultz LD, Barcos M, Bankert RB. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol. 2008; 180(10).
  • Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ, Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007; 178(9).
  • Lou Q, Conway TF, Egilmez NK, Loyall JL, Bernstein SH, Kelleher RJ, Bankert RB. B cell tumor vaccine enhanced by covalent attachment of immunoglobulin to surface proteins on dendritic cells. Clin Immunol. 2006; 118(1).
  • Sabel MS, Hess SD, Egilmez NK, Conway TF, Chen FA, Bankert RB. CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol Immunother. 2005; 54(10).
  • Broderick L, Yokota SJ, Reineke J, Mathiowitz E, Stewart CC, Barcos M, Kelleher RJ, Bankert RB. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells. J Immunol. 2005; 174(2).
  • Lou Q, Kelleher RJ, Sette A, Loyall J, Southwood S, Bankert RB, Bernstein SH. Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood. 2004; 104(3).
  • Anderson TM, Hess SD, Egilmez NK, Nwogu CE, Lenox JM, Bankert RB. Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes. J Cancer Res Clin Oncol. 2003; 129(10).
  • Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol. 2003; 170(1).
  • Egilmez NK, Jong YS, Mathiowitz E, Bankert RB. Tumor vaccination with cytokine-encapsulated microspheres. Methods Mol Med. 2003; 75.
  • Hess, S.D., Egilmez, N.K., Bailey, N., Anderson, T.M., Mathiowitz, E., Bernstein, S.H., Bankert R. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors In Situ by indirect effects of IFN-gamma. J. Immunol.. 2003; 170.
  • Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. Human CD4+ T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma.. J Immunol. 2003; 170(1).
  • Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 2002; 62(24).
  • Egilmez NK, Hess SD, Chen FA, Takita H, Conway TF, Bankert RB. Human CD4+ effector T cells mediate indirect interleukin-12- and interferon-gamma-dependent suppression of autologous HLA-negative lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 2002; 62(9).
  • Bankert RB, Hess SD, Egilmez NK. SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci. 2002; 7.
  • Abra RM, Bankert RB, Chen F, Egilmez NK, Huang K, Saville R, Slater JL, Sugano M, Yokota SJ. The next generation of liposome delivery systems: recent experience with tumor-targeted, sterically-stabilized immunoliposomes and active-loading gradients. J Liposome Res. 2002; 12(1-2).
  • Egilmez, N.K., Hess, S.D., Chen, F-A., Takita, H., Conway, T., Richard Bankert. Human CD4+ Effector T-Cells Mediate an Indirect IL-12 and IFN-gamma-Dependent Suppression of Autologous Lung Tumor Xenografts in SCID Mice. Cancer Res.. 2002.
  • Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases.. Surgery. 2001; 130(3).
  • Sabel MS, Hill H, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery. 2001; 130(3).
  • Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies.. Trends Immunol. 2001; 22(7).
  • Sugano M, Conway TF, Kelleher RJ, Sugiyama Y, Chen FA, Bankert RB, Bernstein SH. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.. J Exp Clin Cancer Res. 2001; 20(2).
  • Sugano M, Conway TF, Kelleher RJ, Sugiyama Y, Chen FA, Bankert RB, Bernstein SH. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response. J Exp Clin Cancer Res. 2001; 20(2).
  • Hess SD, Egilmez NK, Shiroko J, Bankert RB. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.. Cancer Gene Ther. 2001; 8(5).
  • Yamada M, Shiroko T, Kawaguchi Y, Sugiyama Y, Egilmez NK, Chen FA, Bankert RB. CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors.. Int J Cancer. 2001; 92(4).
  • Hess SD, Egilmez NK, Shiroko J, Bankert RB. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model. Cancer Gene Ther. 2001; 8(5).
  • Yamada M, Shiroko T, Kawaguchi Y, Sugiyama Y, Egilmez NK, Chen FA, Bankert RB. CD40-CD40 ligand (CD154) engagement is required but not sufficient for modulating MHC class I, ICAM-1 and Fas expression and proliferation of human non-small cell lung tumors. Int J Cancer. 2001; 92(4).
  • Sugiyama Y, Kato M, Chen FA, Williams SS, Kawaguchi Y, Miya K, Jong YS, Mathiowitz E, Egilmez NK, Bankert RB. Human inflammatory cells within the tumor microenvironment of lung tumor xenograftsmediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J Immunother. 2001; 24(1).
  • Sugiyama, Y., Kato, M., Chen, F-A., Williams, S.S., Kawaguchi, Y., Miya, K., Jong, Y.S., Mathiowitz,E., Egilmez, N.K., Richard Bankert. Human inflammatory cells within the tumor microenvironment of lung tumor xenografts mediate tumor growth suppression in situ that depends on and is augmented by interleukin-12. J. Immunotherapy. 2001; 24.
  • Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice.. Cancer Res. 2000; 60(24).
  • Sugano M, Egilmez NK, Yokota SJ, Chen FA, Harding J, Huang SK, Bankert RB. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 2000; 60(24).
  • Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000; 60(14).
  • Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.. Cancer Res. 2000; 60(14).
  • Bankert RB, Chen FA, Sugiyama Y, Egilmez N. Patient immune response to tumors monitored using SCID mouse models.. Immunol Invest. 2000; 29(2).
  • Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread.. Cancer Immunol Immunother. 2000; 49(2).
  • Egilmez NK, Jong YS, Hess SD, Jacob JS, Mathiowitz E, Bankert RB. Cytokines delivered by biodegradable microspheres promote effective suppressionof human tumors by human peripheral blood lymphocytes in the SCID-Winn model. J Immunother. 2000; 23(2).
  • Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB. Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. J Immunol Methods. 2000; 233(1-2).
  • Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL, Loree TL, Bankert RB. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head Neck. 2000; 22(1).
  • Conway TF, Sabel MS, Sugano M, Frelinger JG, Egilmez NK, Chen F, Bankert RB. Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum.. J Immunol Methods. 2000; 233(1-2).
  • Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD, Hicks WL, Loree TL, Bankert RB. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.. Head Neck. 2000; 22(1).
  • Egilmez, N.K., Jong, Y.S., Hess, S.D., Jacob, J.S., Mathiowitz, E., Richard Bankert. Cytokines delivered by biodegradable microspheres promote effective suppression of human tumors by human peripheral blood lymphocytes in the SCID-Winn model. J. Immunotherapy. 2000; 23.
  • Sabel, M.S., Conway, T.F., Chen, F-A., Richard Bankert. Monoclonal antibodies directed against the T-cell activation molecule CD137 (ILA/4-1BB) block human lymphocyte mediated suppression of tumor xenografts in SCID mice. J. Immunotherapy. 2000; 23.
  • Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model.. Cancer Immunol Immunother. 1998; 46(1).
  • Egilmez NK, Jong YS, Iwanuma Y, Jacob JS, Santos CA, Chen FA, Mathiowitz E, Bankert RB. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model. Cancer Immunol Immunother. 1998; 46(1).
  • Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice. Cancer Res. 1997; 57(14).
  • Iwanuma Y, Chen FA, Egilmez NK, Takita H, Bankert RB. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.. Cancer Res. 1997; 57(14).
  • Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.. Cancer Res. 1996; 56(16).
  • Egilmez NK, Cuenca R, Yokota SJ, Sorgi F, Bankert RB. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery.. Gene Ther. 1996; 3(7).
  • Diamond M, Williams SS, Kida H, Yokota S, Bankert RB. VH and VL gene complexes encoding an anti-spectrin antibody are defined by nucleotide sequencing of cDNA from a hybridoma generated from Hu-PBL-SCID mouse.. Immunol Invest. 1996; 25(4).
  • Egilmez NK, Cuenca R, Yokota SJ, Sorgi F, Bankert RB. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. Gene Ther. 1996; 3(7).
  • Egilmez NK, Iwanuma Y, Bankert RB. Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer. Biochem Biophys Res Commun. 1996; 221(1).
  • Egilmez NK, Iwanuma Y, Bankert RB. Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer.. Biochem Biophys Res Commun. 1996; 221(1).
  • Williams SS, Chen FA, Kida H, Yokata S, Miya K, Kato M, Barcos MP, Wang HQ, Alosco T, Umemoto T, Croy BA, Repasky EA, Bankert RB. Engraftment of human tumor-infiltrating lymphocytes and the production of anti-tumor antibodies in SCID mice.. J Immunol. 1996; 156(5).
  • Bumpers HL, Alosco TR, Wang HQ, Petrelli NJ, Hoover EL, Bankert RB. Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice.. J Surg Res. 1996; 61(1).
  • Cuenca, R.E., Takita, H., Richard Bankert. Orthotopic engraftment of human lung tumors in SCID mice for the study of metastasis. Surg. Oncol.. 1996; 5.
  • Sakakibara, T., Xu, Y., Bumpers, H.L., Chen, F-A., Richard Bankert, Arredondo, M.A., Edge, S.B., Repasky, E.A.. Growth and metastasis of surgical specimens of human breast carcinomas in SCID mice. The Cancer Journal from Scientific American. 1996; 2.
  • Chen FA, Williams SS, Fanslow WC, Bankert RB. Human antibody response in human peripheral blood leukocyte/severe combined immunodeficient chimeric model is dependent on B and T cell costimulation via CD40/CD40 ligand.. J Immunol. 1995; 155(6).
  • Winter DB, Diamond ME, Abu-hadid M, Falkenberg S, Bankert RB. Allelic differences in the VHOx-1 gene explain the absence of a B cell clonal dominance in the primary response of C57BL/6 mice to phthalate.. J Immunol. 1995; 155(5).
  • Falkenberg S, Winter D, Bankert RB. Transient dominance of the early primary immune response by a highly conserved B-cell clone that is distinguished by its lack of memory, high threshold of activation, and a high affinity.. Cell Immunol. 1995; 160(1).
  • Bumpers HL, Alosco TR, Wang HQ, Petrelli NJ, Hoover EL, Bankert RB. Human villous adenomas engrafted into scid mice survive for prolonged period without malignant transformation.. J Clin Invest. 1994; 94(5).
  • Chen FA, Alosco T, Croy BA, Narumi K, Percy DH, Bankert RB. Clones of tumor cells derived from a single primary human lung tumor reveal different patterns of beta 1 integrin expression.. Cell Adhes Commun. 1994; 2(4).
  • Narumi K, Chen FA, Bankert RB, Takita H. Generation of monoclonal antibodies that distinguish between mesotheliomas and other tumor of the lung.. Nippon Geka Hokan. 1994; 63(4).
  • Alosco, T., Gansbacher, B., Richard Bankert, Takita, H., Petrelli, N.. Human lung tumor cell secretion of Interleukin-2 for protection against tumor engraftment. Ann. of Surgical Oncology. 1994; 1(3).
  • Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.. Cancer Res. 1993; 53(17).
  • Williams SS, Alosco TR, Croy BA, Bankert RB. The study of human neoplastic disease in severe combined immunodeficient mice.. Lab Anim Sci. 1993; 43(2).
  • Alosco, T., Croy, B.A., Gansbacher, B., Wang, H-Q., Rao, U., Richard Bankert. Antitumor response independent of functional B or T lymphocytes induced by the local and sustained release of interleukin-2 by the tumor cells. Cancer Immunol. Immunotherap.. 1993; 36.
  • Lou SC, Winter D, Mayers GL, Bankert RB. Nucleotide sequence of messenger RNA encoding VHDJH and VKJK of a highly conserved idiotype-defined primary response anti-hapten antibody.. J Immunol. 1992; 149(12).
  • Williams SS, Umemoto T, Kida H, Repasky EA, Bankert RB. Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies.. J Immunol. 1992; 149(8).
  • Gregorio CC, Kubo RT, Bankert RB, Repasky EA. Translocation of spectrin and protein kinase C to a cytoplasmic aggregate upon lymphocyte activation.. Proc Natl Acad Sci U S A. 1992; 89(11).
  • Klein CE, Dressel D, Steinmayer T, Mauch C, Eckes B, Krieg T, Bankert RB, Weber L. Integrin alpha 2 beta 1 is upregulated in fibroblasts and highly aggressive melanoma cells in three-dimensional collagen lattices and mediates the reorganization of collagen I fibrils.. J Cell Biol. 1991; 115(5).
  • Parikh VS, Nakai C, Yokota SJ, Bankert RB, Tucker PW. COOH terminus of membrane IgM is essential for an antigen-specific induction of some but not all early activation events in mature B cells.. J Exp Med. 1991; 174(5).
  • Chen FA, Repasky EA, Bankert RB. Human lung tumor-associated antigen identified as an extracellular matrix adhesion molecule.. J Exp Med. 1991; 173(5).
  • Ghosh SK, White LM, Ghosh R, Bankert RB. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.. J Immunol. 1990; 145(1).
  • Drake JR, Repasky EA, Bankert RB. Endocytosis of antigen, anti-idiotype, and anti-immunoglobulin antibodies and receptor re-expression by murine B cells.. J Immunol. 1989; 143(6).
  • Chen FA, Repasky EA, Takita H, Schepart BS, Bankert RB. Cell surface glycoprotein associated with human lung tumors that is similar to but distinct from the epidermal growth factor receptor.. Cancer Res. 1989; 49(13).
  • Bankert RB, Yokota S, Ghosh SK, Mayhew E, Jou YH. Immunospecific targeting of cytosine arabinonucleoside-containing liposomes to the idiotype on the surface of a murine B-cell tumor in vitro and in vivo.. Cancer Res. 1989; 49(2).
  • Ghosh SK, Bankert RB. Generation of somatic variants of a B cell hybrid mediated by a non-cytolytic L3T4+ idiotype-specific T cell.. J Immunol. 1989; 142(2).
  • Sugiyama, Y., Saji, S., Takita, H., Richard Bankert. Application of (125) I-labeled monoclonal antibody to the postoperative adjuvant immunotherapy. Biotherapy. 1989; 3.
  • Sugiyama, Y., Saju, S., Takita, H., Richard Bankert. Therapeutic effect of (125)I-labeled monoclonal antibody on human lung tumor xenografts. Biotherapy. 1989; 3.
  • Lee JK, Black JD, Repasky EA, Kubo RT, Bankert RB. Activation induces a rapid reorganization of spectrin in lymphocytes.. Cell. 1988; 55(5).
  • Abu-Hadid MM, Bankert RB, Mayers GL. Selective elimination of idiotype-binding cells in vivo by a drug-idiotype conjugate demonstrates the functional significance of these cells in immune regulation.. Proc Natl Acad Sci U S A. 1988; 85(11).
  • Sugiyama Y, Chen FA, Takita H, Bankert RB. Selective growth inhibition of human lung cancer cell lines bearing a surface glycoprotein gp160 by 125I-labeled anti-gp160 monoclonal antibody.. Cancer Res. 1988; 48(10).
  • Black JD, Koury ST, Bankert RB, Repasky EA. Heterogeneity in lymphocyte spectrin distribution: ultrastructural identification of a new spectrin-rich cytoplasmic structure.. J Cell Biol. 1988; 106(1).
  • Ghosh SK, Patnaik P, Bankert RB. Expression of mu and gamma 1 membrane forms of immunoglobulin segregate in somatic cell hybrids.. Mol Immunol. 1987; 24(12).
  • Hughes CS, Repasky EA, Bankert RB, Johnson RJ, Subjeck JR. Effects of hyperthermia on spectrin expression patterns of murine lymphocytes.. Radiat Res. 1987; 112(1).
  • Abu-hadid MM, Bankert RB, Mayers GL. Antigen-specific drug-targeting used to manipulate an immune response in vivo.. Proc Natl Acad Sci U S A. 1987; 84(20).
  • Reddy S, Piccione D, Takita H, Bankert RB. Human lung tumor growth established in the lung and subcutaneous tissue of mice with severe combined immunodeficiency.. Cancer Res. 1987; 47(9).
  • Luo SC, Bankert RB. A new cross-reactive idiotype-defined family in the phthalate humoral immune response of mice. I. Linkage of VH-Xmp to IgCH allotype locus and mapping with respect to other known VH genes.. J Immunol. 1987; 138(7).
  • Ghosh SK, Wong J, Bankert RB. Idiotype-specific T lymphocytes responsible for the selection of somatic variants of a B cell hybrid.. J Immunol. 1987; 138(7).
  • Richard Bankert, Repasky, E.A., Mazzaferro, P.K., Kubo, R.T.. Generation and use of an antigen-specific hybrid to study B-cell function. J. Mol. Cell. Immunol.. 1987; 3.
  • Mazzaferro, P.K., Repasky, E.A., Black, J., Kubo, R.T., Richard Bankert. Biochemical and ultrastructural characterization of a novel cell structure associated with immunoglobulin secretion of B-lymphocytes. J. Molec. Cell Immunol.. 1987; 3.
  • Zylstra S, Chen FA, Ghosh SK, Repasky EA, Rao U, Takita H, Bankert RB. Membrane-associated glycoprotein (gp 160) identified on human lung tumors by a monoclonal antibody.. Cancer Res. 1986; 46(12 Pt).
  • Pauly JL, Bankert RB, Repasky EA. Immunofluorescent patterns of spectrin in lymphocyte cell lines.. J Immunol. 1986; 136(1).
  • Saji, S., Kato, K., Sakata, H., Takita, H., Richard Bankert. The production and the clinical application of monoclonal antibodies against human lung carcinoma. Oncologia. 1986; 18.
  • Schepart BS, Abu-Hadid M, Mayers GL, Bankert RB. Antibody response of BALB/c mice to dextran B1355S: alterations in the expression of an idiotype associated with the depletion of idiotype-binding cells.. J Immunol. 1985; 135(3).
  • Schepart BS, Mayers GL, Bankert RB. Failure of PFC inhibition assays to distinguish idiotypically between clonotypes that are readily distinguishable by RIA analysis.. J Immunol. 1985; 135(3).
  • Luo SC, Bankert RB. Cross-reactive idiotype family observed in the phthalate-specific B cell repertoire of adult BALB/c mice: diversity of IgM compared with IgG monoclonal anti-phthalate antibodies.. J Immunol. 1985; 135(2).
  • Raza, A., Spiridonidis, C., Ucar, K., Mayers, G.L., Richard Bankert, Preisler, H.. Double labelling with anti-Brdu antibody and titrated thymidine. Cancer Research. 1985; 45.
  • Lou, S-C., Richard Bankert. Monoclonal antibodies specific for the mouse IgG1 allotype determinants: Reactivity with inbred and outbred mice. J. Immunol.. 1985; 4.
  • Ghosh SK, Bankert RB. Generation of heavy chain-loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells.. J Immunol. 1984; 133(3).
  • Repasky EA, Symer DE, Bankert RB. Spectrin immunofluorescence distinguishes a population of naturally capped lymphocytes in situ.. J Cell Biol. 1984; 99(1 Pt).
  • Richard Bankert, Jou, Y-H., Mayers, G.L.. Monoclonal Immunoglobulins derived from myelomas and hybridomas. Molecular Immunology. 1984.
  • Saji, S., Zylstra, S., Schepart, B.S., Ghosh, S.K., Jou, Y-H., Takita, H., Richard Bankert. Monoclonal antibodies specific for two different histological types of human lung carcinoma. Hybridoma. 1984; 3.
  • Richard Bankert. Development and use of monoclonal antibodies in the treatment of cancer. Cancer Drug Delivery. 1984; 1.
  • Richard Bankert, Mayhew, E., Yokota, S., Jou, Y-H.. Immunospecific tumor targeting of drug containing liposomes. Antibodies, Protective, Destructive and Regulatory Role. 1984.
  • Jou YH, Luo SC, Bankert RB. A filtration double antibody radioimmunoassay that simplifies and semi-automates the isolation of immune precipitates.. J Immunol Methods. 1983; 65(3).
  • Jou, Y-H., Mazzaferro, P.K., Mayers, G.L., Richard Bankert. Methods for the attachment of haptens and proteins to erythrocytes. Methods in Enzymmology. 1983; 92.
  • Richard Bankert. Rapid screening and replica-plating of hybridomas for the production and characterization of monoclonal antibodies. Methods in Enzymmology. 1983; 92.
  • Bloor AG, Jou Y, Hoeplinger C, Gartner JE, Mayers GL, Bankert RB. Hapten-specific B cell repertoire probed by hybridoma technology: selection and characterization of representative clonotypes from the antibody-forming cell pool.. J Immunol. 1982; 128(3).
  • Bankert RB, Bloor AG, Jou YH. Idiotypes: their presence on B- and T-lymphocytes and their role in the regulation of the immune response.. Vet Immunol Immunopathol. 1982; 3(1-2).
  • Jou, Y-H., Schepart, B.S., Richard Bankert. Monoclonal antibodies and a heterobifunctional reagent: a novel approach to the vectoral labeling of selected membrane proteins. Immunol. Commun.. 1982; 11.
  • Jou YH, Bankert RB. Coupling of protein antigens to erythrocytes through disulfide bond formation: preparation of stable and sensitive target cells for immune hemolysis.. Proc Natl Acad Sci U S A. 1981; 78(4).
  • Richard Bankert, Mazzaferro, D., Mayers, G.L.. Hybridomas producing hemolytic plaques used to study the relationship between monoclonal antibody affinity and the efficiency of plaque inhibition with increasing concentrations of antigen. Hybridoma. 1981; 1.
  • Richard Bankert, Mayers, G. L.. Immune response of BALB/c mice to phthalate: Characterization of a new and useful model for studying immune regulation. Immunol. Commun.. 1981; 10.
  • Bankert RB, Mayers GL. Use of hybridoma technology to assess the antibody repertoire to a negatively charged hapten.. Transplant Proc. 1980; 12(3).
  • Mayers GL, Bankert RB. Immunochemistry of monoclonal antibodies.. Transplant Proc. 1980; 12(3).
  • Bankert RB, DesSoye D, Powers L. Antigen-promoted cell fusion: antigen-coated myeloma cell fuse with antigen-reactive spleen cells.. Transplant Proc. 1980; 12(3).
  • Richard Bankert, Des Soye, D., Powers, L.. Screening and replica plating of anti-hapten hybridomas with a transfer template hemolytic spot assay. J. Immunol. Methods. 1980; 35.
  • Pressman, D., Richard Bankert. Lymphocyte hibridomas: current and anticipated application in cancer ans transplantation research. J. Sur. Oncology. 1980; 15.
  • Bankert RB, Mayers GL, Pressman D. Synthesis of a lipopolysaccharide designed to conjugate haptens and proteins to erythrocyte for use as target cells in passive hemagglutination and hemolytic assays.. J Immunol. 1979; 123(6).
  • Bankert RB, Mayers GL, Pressman D. Clearance and re-expression of a myeloma cell's antigen-binding receptors induced by ligands known to be immunogenic or tolerogenic for normal B lymphocytes: a model to study membrane events associated with B cell tolerance.. Eur J Immunol. 1978; 8(7).
  • Mayers GL, Bankert RB, Pressman D. Comparison of the homogeneous, primary anti-dextran B1355 antibody raised in BALB/c mice with protein 104E.. J Immunol. 1978; 120(4).
  • Bankert RB, Mayers GL, Pressman D. Mechanisms of B cell tolerance. I. Tolerance to dextran B1355 induced with the oxidized dextran.. J Immunol. 1977; 118(4).
  • Bankert RB, Wolf B, Pressman D. Antigen-specific receptors on antibody-forming cells expressing light and heavy chain determinants.. Cell Immunol. 1976; 27(1).
  • Bankert RB, Pressman D. Receptor-blocking factor present in immune serum resembling auto-anti-idiotype antibody.. J Immunol. 1976; 117(2).
  • Bankert RB, Wolf B. Rosette-plaque assay: fine specificity differences among individual hapten-primed lymph node cells.. J Immunol. 1974; 112(5).
  • Richard Bankert, Wolf, B.. Fine specificity differences among individual hapten-primed lymph node cells. J. Immunol.. 1974; 112.
  • Bankert RB, Wolf B. Simultaneous expression of hapten binding and antibody secretion by NIP-primed lymph node cells early in the immune response.. J Immunol. 1973; 111(6).
See All (133 Total) >
Books and Book Chapters:
  • Egilmez, N.K., Jong, Y.S., Mathiowitz, E., Richard Bankert. Tumor vaccination with cytokine-encapsulated microspheres. Methods in Molecular Medicine. 2001.
  • Mazzaferro, P.K., Richard Bankert. Biochemistry of immunoglobulins. The Clinical Chemistry of Laboratory Animals. 1999.
  • Richard Bankert, Umemoto, T., Sugiyama, Y., Chen, F.A., Repasky, E., Yokota, S.. Human lung tumors, patients' peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in SCID mice. proc. of the EMBO Workshop on the SCID Mouse, Basell, Switzerland, Feb. 1989. Curr. Topics In Microbiol. and Immunol.. 1989; 152.
  • Lou, S-C., Richard Bankert. Use of congenic and recombinant inbred mouse strains to link a highly conserved idiotypic marker to an Igh-C region allotype locus and to map this new member of the Q52 gene family within the Igh-V gene complex. H-2 Antigens, Genes and Molecules, Function. 1988; 144.
  • Richard Bankert, Abbas, A.K.. Myelomas as models to study activation and suppression of normal lymphocytes. Progress in Myelomas. 1980.


Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

217 Biomedical Research Building
Buffalo, NY 14214
Phone: (716) 829-2701
Email: rbankert@buffalo.edu


Log in to Update Your Profile
"); pageTracker._trackPageview();